source
- Atea's hepatitis C combo therapy shows non-inferior results to Gilead's EpclusaAtea Pharmaceuticals announced that its oral combination of bemnifosbuvir and ruzasvir met the predefined non-inferiority criteria when compared with Gilead's Epclusa for treating hepatitis C. The…
- Novo Nordisk loses bid to dismiss lawsuit over CagriSema trial readoutU.S. District Judge Robert Kirsch in New Jersey refused to dismiss most of the securities lawsuit filed by investors after Novo Nordisk’s CagriSema readout. While the judge found the plaintiffs’ cl…